drugset / Trial / NCT00657449

A Double-blind, Double-dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain

NCT00657449

Phase 4 Terminated 45 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The study compares valdecoxib 40 mg once daily vs. rofecoxib 50 mg one daily in treating the signs and symptoms of acute first- or second-degree ankle sprain. The study also evaluated the disability status, tolerability and safety of these treatments.

Timeline

Start
2003-06-04
Primary completion
2004-10-01
Completion
2004-10-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator rofecoxib Small molecule 50 mg Oral
Comparator valdecoxib Small molecule 40 mg Oral

Indications

No indication recorded.